Some Necessary Additional Points
- PMID: 29968561
- PMCID: PMC6050430
- DOI: 10.3238/arztebl.2018.0417a
Some Necessary Additional Points
Comment in
-
In Reply.Dtsch Arztebl Int. 2018 Jun 15;115(24):417-418. doi: 10.3238/arztebl.2018.0417b. Dtsch Arztebl Int. 2018. PMID: 29968562 Free PMC article. No abstract available.
Comment on
-
Molecular Imaging in Oncology Using Positron Emission Tomography.Dtsch Arztebl Int. 2018 Mar 16;115(11):175-181. doi: 10.3238/arztebl.2018.0175. Dtsch Arztebl Int. 2018. PMID: 29607803 Free PMC article. Review.
References
-
- Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin‘s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–1799. - PubMed
-
- Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin‘s lymphoma. N Engl J Med. 2015;372:1598–1607. - PubMed
-
- Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32:1188–1194. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources